Angiochem to work with GSK on lysosomal disorders
Angiochem Inc of Canada has secured a new global collaboration with GlaxoSmithKline Plc to develop a new enzyme replacement therapy for a lysosomal storage disease. The deal features an upfront payment of up to $31.5 million.